drugset / Trial / NCT02291055
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of the cervix or metastatic human papillomaviruses (HPV)+ squamous cell carcinoma of the head and neck (SCCHN).
Timeline
- Start
- 2015-04
- Primary completion
- 2019-07-09
- Completion
- 2020-11-20
Publications
- Results Slomovitz BM, Moore K, Vangala S, Parsi M, Sheerie S, John Heyburn J ,Posner M. Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer. Annual Meeting on Women's Cancer. March 28-31, 2020. Toronto Canada.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADXS11-001 | Vaccine | 1e+09 unknown | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |